Addition of Isatuximab to RVd as Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma (GMMG-HD7)
January 27th 2022
Expert hematologist/oncologist Joseph Mikhael, MD, shares insight on the phase III GMMG-HD7 trial, which added isatuximab to RVd in the setting of newly diagnosed, transplant-eligible multiple myeloma.